
Immix Biopharma, Inc. — Investor Relations & Filings
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for serious diseases. The company's primary strategy is to advance Chimeric Antigen Receptor T-cell (CAR-T) therapies by addressing their key limitation: neurotoxicity. By working to overcome this side effect, ImmixBio aims to expand the use of CAR-T treatments to a wider range of patients, medical centers, and new indications, with a lead program targeting AL Amyloidosis. The company is also developing a novel class of Tissue-Specific Therapeutics (TSTx) for applications in oncology and inflammation.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K | 2026-05-29 | English | |
| 8-K | 2026-05-21 | English | |
| 424B5 | 2026-05-21 | English | |
| FWP | 2026-05-21 | English | |
| 8-K | 2026-05-21 | English | |
| 10-Q - Immix Biopharma, Inc. (0001873835) (Filer) | 2026-05-07 | English |
Browse filings by year
6 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 47894489 | 8-K | 2026-05-29 | English | ||
| 46754062 | 8-K | 2026-05-21 | English | ||
| 46754084 | 424B5 | 2026-05-21 | English | ||
| 46728248 | FWP | 2026-05-21 | English | ||
| 46726620 | 8-K | 2026-05-21 | English | ||
| 43596377 | 10-Q - Immix Biopharma, Inc. (0001873835) (Filer) | 2026-05-07 | English | ||
| 33642490 | DEF 14A - Immix Biopharma, Inc. (0001873835) (Filer) | 2026-04-06 | English | ||
| 33092916 | 8-K - Immix Biopharma, Inc. (0001873835) (Filer) | 2026-03-30 | English | ||
| 33066426 | 10-K/A - Immix Biopharma, Inc. (0001873835) (Filer) | 2026-03-27 | English | ||
| 33043171 | S-8 - Immix Biopharma, Inc. (0001873835) (Filer) | 2026-03-25 | English | ||
| 33043144 | 8-K - Immix Biopharma, Inc. (0001873835) (Filer) | 2026-03-25 | English | ||
| 33043132 | 424B5 - Immix Biopharma, Inc. (0001873835) (Filer) | 2026-03-25 | English | ||
| 33043109 | 10-K - Immix Biopharma, Inc. (0001873835) (Filer) | 2026-03-25 | English | ||
| 33002269 | SCHEDULE 13G - Immix Biopharma, Inc. (0001873835) (Subject) | 2026-03-20 | English | ||
| 32145665 | SCHEDULE 13G Filing | 2026-02-17 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Ajanta Pharma Ltd.
Specialty pharmaceutical firm focused on complex generics a…
|
AJANTPHARM | IN | Manufacturing |
|
Akari Therapeutics Plc
Develops next-gen antibody-drug conjugates using proprietar…
|
AKTX | US | Manufacturing |
|
Akebia Therapeutics, Inc.
A biopharmaceutical company that develops and commercialize…
|
AKBA | US | Manufacturing |
|
Akeso, Inc.
Global commercial-stage biopharma developing innovative ant…
|
9926 | KY | Manufacturing |
|
Aktis Oncology, Inc.
A clinical-stage biotech developing targeted alpha radiopha…
|
AKTS | US | Manufacturing |
|
Akums Drugs and Pharmaceuticals Limited
CDMO providing end-to-end pharmaceutical manufacturing and …
|
AKUMS | IN | Manufacturing |
|
Albert David Ltd.
Produces pharmaceutical formulations, infusions, and specia…
|
ALBERTDAVD | IN | Manufacturing |
|
Aldeyra Therapeutics, Inc.
Develops medications for immune-mediated ocular and systemi…
|
ALDX | US | Manufacturing |
|
Aleafia Health Inc.
Vertically integrated cannabis company with cultivation, pr…
|
AH | CA | Manufacturing |
|
Alector, Inc.
Clinical-stage biotech using immuno-neurology to treat neur…
|
ALEC | US | Manufacturing |
Immix Biopharma, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34423/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34423 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34423 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34423 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34423}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Immix Biopharma, Inc. (id: 34423)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.